Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
88 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
000975-C
Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples from Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Myeloid Leukemia
000867-CC
Humanitarian Use Device (HUD) Protocol for Use of Miltenyi CliniMACS (Registered Trademark) CD34 Reagent System in AML
Participants currently recruited/enrolled
0-125 Years
CC
Myeloid Leukemia
000732-C
A Long-Term Follow-Up Study of Patients Who Received VOR33
Recruitment has not started
18-125 Years
NCI
Myeloid Leukemia
000731-C
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse following Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-70 Years
NCI
Myeloid Leukemia
000661-C
Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult Myelodysplastic Syndromes (MDS)
Participants currently recruited/enrolled
0-125 Years
NCI
Myeloid Leukemia
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
Myeloid Leukemia
20-H-0016
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Myeloid Leukemia
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
Myeloid Leukemia
19-HG-0059
Longitudinal Studies of Patients with FPDMM
Participants currently recruited/enrolled
0-125 Years
NHGRI
Myeloid Leukemia
17-H-0026
Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia
Completed Study; data analyses ongoing
18-99 Years
NHLBI
Myeloid Leukemia
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Myeloid Leukemia
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Myeloid Leukemia
02-I-0286
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Participants currently recruited/enrolled
2-125 Years
NIAID
Myeloid Leukemia
000923-H
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors
Participants currently recruited/enrolled
18-110 Years
NHLBI
Leukemia
000792-C
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults with B Lineage Acute Lymphobla
Recruitment has not started
1-25 Years
NCI
Leukemia
000631-C
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy
Recruitment has not started
5-125 Years
NCI
Leukemia
000539-H
Addition of JSP191 (c-kit antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia
Participants currently recruited/enrolled
4-100 Years
NHLBI
Myeloid
000509-C
An Open Label, Multi-Center Roll-Over Study to Assess Long-Term Safety in Patients Who are Ongoing or Have Completed a Prior Global Novartis or GSK Sponsored Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Study and are Judged by the Investigator to B
Enrolling by Invitation
18-125 Years
NCI
Leukemia
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Leukemia
000464-H
Evaluation of Clonal Hematopoiesis in Patients with Sickle Cell Disease Receiving Curative Therapies
Enrolling by Invitation
4-125 Years
NHLBI
Leukemia
000444-H
Vaccine Responses in Patients with B Cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Leukemia
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Leukemia
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Leukemia
000124-C
A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Recruitment has not started
2-21 Years
NCI
Leukemia
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Participants currently recruited/enrolled
2-125 Years
NCI
Leukemia
21-C-0019
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients with Relapsed/Refractory Hairy Cell Leukemia and Variant
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
20-C-0076
Phase 2 Trial of Encorafenib plus Binimetinib for Patients with BRAF V600 Mutated Relapsed/Refractory HCL
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
20-C-0075
Phase 2 Trial for Binimetinib for Patients with Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
Leukemia
19-H-0139
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Participants currently recruited/enrolled
18-125 Years
NHLBI
Myeloid
19-H-0118
Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism Levels
Participants currently recruited/enrolled
2-80 Years
NHLBI
Myeloid
19-H-0111
Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Leukemia
19-H-0001
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
No longer recruiting/follow-up only
18-125 Years
NHLBI
Leukemia
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-125 Years
NCI
Leukemia
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Leukemia
19-C-0042
A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Leukemia
18-C-0080
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled Trial
Completed Study; data analyses ongoing
5-125 Years
NCI
Leukemia
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Leukemia
18-C-0026
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Participants currently recruited/enrolled
1-21 Years
NCI
Leukemia
17-H-0118
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Leukemia
17-C-0137
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
3-65 Years
NCI
Leukemia
17-C-0028
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo ) in Combination with Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
Completed Study; data analyses ongoing
2-21 Years
NCI
Leukemia
16-C-0062
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
Leukemia
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Leukemia
15-H-0016
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.
No longer recruiting/follow-up only
18-125 Years
NHLBI
Leukemia
15-C-0141
Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies
Enrolling by Invitation
18-125 Years
NCI
Leukemia
15-C-0093
Phase I Trial of Turalio(R) (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Participants currently recruited/enrolled
3-35 Years
NCI
Leukemia
15-C-0067
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Leukemia
14-C-0131
A Phase II, Open-Label Study in Patients With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib
Completed Study; data analyses ongoing
18-125 Years
NCI
Leukemia
13-N-0135
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Completed Study; data analyses ongoing
18-125 Years
NINDS
Leukemia
13-I-0157
The Natural History of GATA2 Deficiency and Related Disorders
Participants currently recruited/enrolled
2-100 Years
NIAID
Leukemia
13-H-0116
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Participants currently recruited/enrolled
4-125 Years
NHLBI
Leukemia
13-C-0132
Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome
Participants currently recruited/enrolled
8-70 Years
NCI
Leukemia
13-C-0006
Phase I/II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Smoldering and Chronic Adult T-cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
Leukemia
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Leukemia
12-C-0193
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
12-C-0160
Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Adults with Chronic Illness and their Parents
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Leukemia
11-I-0007
Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined Immunodeficiency
Clinical hold/Recruitment or enrollment suspended
2-40 Years
NIAID
Leukemia
11-C-0255
Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome
Participants currently recruited/enrolled
0-125 Years
NCI
Leukemia
11-C-0242
Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition
Participants currently recruited/enrolled
3-125 Years
NCI
Leukemia
11-C-0136
Multi-Institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-Pubertal Children and Adults with Molecular Imaging Evaluation
Completed Study; data analyses ongoing
2-55 Years
NCI
Leukemia
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Leukemia
10-C-0086
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Participants currently recruited/enrolled
0-125 Years
NCI
Leukemia
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
No longer recruiting/follow-up only
18-75 Years
NCI
Leukemia
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
09-H-0199
A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R agonist), Eltrombopag, in Patients with Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Leukemia
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
Leukemia
09-C-0025
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Leukemia
09-C-0005
Randomized Trial of Cladribine (CdA) with Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Leukemia
08-H-0105
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Leukemia
07-C-0195
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea
Completed Study; data analyses ongoing
18-74 Years
NCI
Leukemia
06-H-0190
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders with Alemtuzumab (Campath)
Completed Study; data analyses ongoing
18-85 Years
NHLBI
Leukemia
06-C-0150
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Leukemia
05-H-0242
A Pilot Study of Alemtuzumab (Campath) in Patients with Relapsed or Refractory Severe Aplastic Anemia
Completed Study; data analyses ongoing
2-110 Years
NHLBI
Leukemia
05-H-0130
Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants
Participants currently recruited/enrolled
7-80 Years
NHLBI
Leukemia
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Leukemia
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Leukemia
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Participants currently recruited/enrolled
0-125 Years
NCI
Leukemia
99-H-0050
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
Completed Study; data analyses ongoing
2-80 Years
NHLBI
Leukemia
98-N-0047
Immuno-Virological Evaluation of Human T Cell Leukemia Virus Type-1 Associated Myelopathy (HAM/TSP)
Participants currently recruited/enrolled
18-125 Years
NINDS
Leukemia
96-H-0049
Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic Transplantation
Participants currently recruited/enrolled
18-60 Years
NHLBI
Leukemia
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Participants currently recruited/enrolled
12-125 Years
NCI
Leukemia